Although survival of each patient has improved based on the emergence of these targeted therapies partly, the prognosis can be extremely variable.[7] It’s not completely understood how the tumor characteristics and other patients’ factors influence the treatment benefit and prognosis of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.